FDA extends review of Merck & Co\'s Keytruda in lung cancer use

FDA extends review of Merck & Co's Keytruda in lung cancer use

US regulators have pushed back the deadline for their review of Merck & Co’s immunotherapy Keytruda in certain patients with untreated lung cancer, after the pharmaceutical company submitted new data. US-based Merck & Co is asking the FDA ...

Original Article: FDA extends review of Merck & Co's Keytruda in lung cancer use

More From BioPortfolio on "FDA extends review of Merck & Co's Keytruda in lung cancer use"